Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Randomized Trial Comparing Total Androgen Blockade Versus Total Androgen Blockade Plus Pelvic Irradiation in Clinical Stage T3-4, N0, M0 Adenocarcinoma of the Prostate.

Trial Profile

Phase III Randomized Trial Comparing Total Androgen Blockade Versus Total Androgen Blockade Plus Pelvic Irradiation in Clinical Stage T3-4, N0, M0 Adenocarcinoma of the Prostate.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Antiandrogens; Bicalutamide; Buserelin; Flutamide; Goserelin; Leuprorelin; Nilutamide
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 03 Apr 2020 Biomarkers information updated
  • 21 Sep 2013 Additional lead trial centre added as reported by ClinicalTrials.gov.
  • 05 Jun 2012 Final analysis presented at the 48th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top